2. Search Result
Search Result
Results for "

neonatal mice

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Peptides

4

Inhibitory Antibodies

2

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N3018
    Isomaltose

    6-O-α-D-Glucopyranosyl-D-glucose; D-Isomaltose

    		 Endogenous Metabolite Parasite Infection Metabolic Disease
    Isomaltose (6-O-α-D-Glucopyranosyl-D-glucose) is a glucose disaccharide. Isomaltose induces G-CSF secretion via heat-induced oxidative polymerization of glucose groups into high-molecular-weight compounds. Isomaltose modulates cecal bacterial cluster structure in mice. Isomaltose exhibits low glycemic index, slow hydrolysis, and prebiotic properties. Isomaltose reduces in vivo Cryptosporidium parvum colonization in neonatal mice. Isomaltose can be used for the research of Cryptosporidium parvum infection .
    Isomaltose
  • HY-P990129
    Anti-Mouse CD71/TfR1 Antibody (8D3)

    		Transferrin Receptor Infection
    Anti-Mouse CD71/TfR1 Antibody (8D3) is a rat-derived anti-mouse CD71/TfR1 IgG2a type antibody inhibitor. Anti-Mouse CD71/TfR1 Antibody (8D3) depletes of CD71+ erythroid cells but does not change percentages of Tregs in neonatal mice. Anti-Mouse CD71/TfR1 Antibody (8D3) enhances neonatal mice defence against infection .
    Anti-Mouse CD71/TfR1 Antibody (8D3)
  • HY-W203683
    Perfluorononanoic acid

    PFNA; Heptadecafluorononanoic acid

    		 PPAR PERK Metabolic Disease
    Perfluorononanoic acid (PFNA) is an orally active PPARα activator. Perfluorononanoic acid activates PPARα-mediated gene expression, including upregulating target genes associated with lipid metabolism and triglyceride storage. Perfluorononanoic acid exhibits certain developmental and reproductive toxicity. Perfluorononanoic acid causes hepatomegaly in pregnant mice, induces high postnatal mortality in neonatal mice, and leads to dose-dependent delays in eye-opening time and puberty onset in mouse offspring .
    Perfluorononanoic acid
  • HY-149648
    JNJ-8003

    		RSV DNA/RNA Synthesis Infection
    JNJ-8003 is a potent and orally active non-nucleoside RSV polymerase inhibitor with an IC50 of 0.29 nM. JNJ-8003 targets the L protein polymerase complex of RSV (IC50 = 0.67 nM), and blocks the transcription and replication of the viral genome by inhibiting the activity of RNA-dependent RNA polymerase (RdRp). JNJ-8003 displays subnanomolar activity in vitro as well as prominent efficacy in mice and a neonatal lamb models. JNJ-8003 can be used for the study of respiratory syncytial virus (RSV) .
    JNJ-8003
  • HY-P1684
    Peptide P60
    1 Publications Verification

    FOXP3 inhibitor P60

    		 NF-κB Nuclear Factor of activated T Cells (NFAT) Infection Inflammation/Immunology Cancer
    Peptide P60 is a FOXP3 inhibitor. Peptide P60 reduces the nuclear translocation of FOXP3 and impairs FOXP3-mediated inhibition of NF-κB and NFAT activity. Peptide P60 inhibits the immunosuppressive activity of regulatory T cells and restores the proliferation and activation of effector T cells. Peptide P60 induces lymphoproliferative autoimmune syndrome in neonatal ICR mice and reduces the number of CD4 +CD25 +Foxp3 + T cells in the spleen. Peptide P60 enhances the efficacy of AH1 (HY-P4193) peptide vaccine and recombinant adenovirus-based HCV NS3 vaccine in BALB/c mice, including protective effects against CT26 tumor implantation. Peptide P60 can be used in studies related to tumor immunity, viral infection and lymphoproliferative autoimmune syndrome .
    Peptide P60
  • HY-P99976
    Anti-Mouse CD19 Antibody (1D3)

    		CD19 Inflammation/Immunology
    Anti-Mouse CD19 Antibody (1D3) is an IgG2a antibody inhibitor targeting mouse CD19. Anti-Mouse CD19 Antibody (1D3) reduces CD19 expression levels on the surface of B cells. Anti-Mouse CD19 Antibody (1D3) inhibits the replication of peritoneal B-1a cells .
    Anti-Mouse CD19 Antibody (1D3)
  • HY-172705
    DSPE-PEG2000-RVG29

    		Liposome nAChR Neurological Disease
    DSPE-PEG2000-RVG29 is a PEG conjugate composed of DSPE and rabies virus glycoprotein 29 (RVG29). RVG29 specifically binds to nicotinic acetylcholine receptors (nAChR) at the blood-brain barrier (BBB), crosses the BBB, and mediates receptor-dependent transcytosis. DSPE-PEG2000-RVG29 can be used for brain-targeted drug delivery, surface modification of nanocarriers, as well as gene and nucleic acid delivery. DSPE-PEG2000-RVG29 is applicable to research related to hypoxic-ischemic brain injury, Parkinson's disease, and other conditions .
    DSPE-PEG2000-RVG29
  • HY-33015A
    4-Chlorocinnamaldehyde

    trans-p-Chlorocinnamaldehyde

    		 Enterovirus Infection
    4-Chlorocinnamaldehyde (trans-p-Chlorocinnamaldehyde) is an antiviral agent. 4-Chlorocinnamaldehyde inhibits the replication of Coxsackievirus B3 in cardiomyocytes, but shows poor efficacy in animal experiments. 4-Chlorocinnamaldehyde can be used in studies related to viral myocarditis .
    4-Chlorocinnamaldehyde
  • HY-A0114
    Moexiprilat

    RS 10029

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Moexiprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC50=2.1 nM) and an active metabolite of the prodrug Moexipril (HY-117281). It is formed from moexipril in vivo by side chain ester hydrolysis. Moexiprilat (10 nM) prevents the estrone- or angiotensin II-stimulated proliferation of primary neonatal rat cardiac fibroblasts. It reduces mean arterial blood pressure and increases the levels of atrial natriuretic peptide, a marker of hypertension, in ovariectomized mice when administered at a dose of 50 mg/kg per day.
    Moexiprilat
  • HY-P10110
    retro-inverso TAT-Beclin 1 (D-amino acid)

    		Autophagy Neurological Disease
    retro-inverso TAT-Beclin 1 D-amino acid is has higher activity and resistance to proteolytic degradation in vivo compared to L-amino acids peptide. TAT-Beclin 1 can induce autophagy in peripheral tissues in adult mice as well as in the central nervous system of neonatal mice .
    retro-inverso TAT-Beclin 1 (D-amino acid)
  • HY-N3018R
    Isomaltose (Standard)

    6-O-α-D-Glucopyranosyl-D-glucose (Standard); D-Isomaltose (Standard)

    		 Reference Standards Endogenous Metabolite Parasite Infection Metabolic Disease
    Isomaltose (Standard) is the analytical standard of Isomaltose (HY-N3018). This product is intended for research and analytical applications. Isomaltose induces G-CSF secretion via heat-induced oxidative polymerization of glucose groups into high-molecular-weight compounds. Isomaltose modulates cecal bacterial cluster structure in mice. Isomaltose exhibits low glycemic index, slow hydrolysis, and prebiotic properties. Isomaltose reduces in vivo Cryptosporidium parvum colonization in neonatal mice. Isomaltose can be used for the research of Cryptosporidium parvum infection .
    Isomaltose (Standard)
  • HY-157082
    ZHSI-1

    		Enterovirus Infection
    ZHSI-1 is an EV71 (Enterovirus 71) inhibitor that inhibits EV71/CVA16 replication and virus-induced pyroptosis associated with viral pathogenesis. ZHSI-1 effectively prevents EV71 infection in neonatal and young mice in animal models. ZHSI-1 can be used to study viral infections such as hand, foot and mouth disease (HFMD) .
    ZHSI-1
  • HY-106761
    Oxodipine

    		Calcium Channel Cardiovascular Disease Others
    Oxodipine, a dihydropyridine-type calcium antagonist, inhibits KCl-induced aortic contraction in rabbits and reduces cardiac force in less potent rat ventricular test-paper contractions. In rat cultured neonatal ventricular myocytes, Oxodipine reduces L-type Ca currents (I) with an IC50 of 0.24 μM, and against T-type Ca currents (I) with an IC50 of 0.41 μM. Oxodipine causes constipation in mice and gingival hyperplasia in dogs .
    Oxodipine
  • HY-162729
    LSD1-IN-34

    		Histone Demethylase Monoamine Oxidase TGF-beta/Smad Cardiovascular Disease
    LSD1-IN-34 (Compound 7d) is the orally active inhibitor for Lysine-specific demethylase (LSD) and monoamine oxidase (MAO), with IC50 of 4.51 and 18.46 nM, for LSD1 and MAO A. LSD1-IN-34 inhibits the Ang II-induced neonatal rat myocardial fibroblasts (NRCFs) activation, without significant toxicity (20 μM). LSD1-IN-34 inhibits TGFβ/Smad signaling pathway, and ameliorates heart failure in mice. LSD1-IN-34 exhibits good pharmacokinetic characteristics in rats .
    LSD1-IN-34
  • HY-120291
    ASP9436

    		Phosphodiesterase (PDE) Neurological Disease
    ASP9436 is an orally active and blood-brain barrier permeable PDE10A inhibitor with an IC50 of 8 nM against human PDE10A. ASP9436 attenuates locomotor activity in mouse hyperactivity models and ameliorates visual recognition memory impairment in neonatal mice. ASP9436 is applicable to research related to schizophrenia .
    ASP9436
  • HY-P992482
    VIR-2482

    		Drug Derivative Influenza Virus Fc Receptor (FcR) Complement System Infection
    VIR-2482 is a monoclonal antibody targeting influenza A hemagglutinin (HA). VIR-2482 is generated by introducing LS mutations (M428L/N434S) into the Fc region of MEDI8852 (HY-P991446). VIR-2482 binds to the conserved HA stem epitope across all 18 influenza A HA subtypes, neutralizes a broad spectrum of H1N1 and H3N2 strains, binds to FcγRIIIa, FcγRIIa and C1q, and induces antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. VIR-2482 reduces morbidity and mortality caused by seasonal influenza A strains and provides prophylactic protection in mice. VIR-2482 can be used in research related to influenza A disease .
    VIR-2482
  • HY-P11791
    nNIF peptide

    		Endogenous Metabolite Infection
    nNIF peptide is an endogenous polypeptide detectable in human umbilical cords and neonatal blood. nNIF peptide specifically inhibits neutrophil extracellular trap (NETs) formation by neutrophils without interfering with other key immune functions of neutrophils. nNIF peptide can be used in studies related to COVID-19 acute respiratory distress syndrome, polymicrobial sepsis, and neonatal infectious peritonitis .
    nNIF peptide
  • HY-P992152
    Vatreptacog alfa

    		Factor VIIa Drug Derivative Cardiovascular Disease
    Vatreptacog alfa is a recombinant hFVIIa analog, differing from native FVIIa by three amino acid substitutions (V158D, E296V and M298Q) in the protease domain. Vatreptacog alfa exhibits enhanced tissue factor-independent enzymatic activity toward activated platelets. Vatreptacog alfa can be used in the research of hemophilia .
    Vatreptacog alfa

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: